kristoff@GENBANK.BIO.NET (Dave Kristofferson) (03/01/91)
NOTE: The NIH Guide may be split into more than one mail message to
avoid truncation during e-mail distribution. The first message always
begins with the RFP/RFA summary sections followed by the appended
texts of the full RFP/RFAs.
----------------------------------------------------------------------
$$XID NIHGUIDE 19910301 V20N09 P1O1 ************************************
X-comment: RFAs described: AG-91-09, LM-91-01, NR-91-02
NIH GUIDE - Vol. 20, No. 9, March 1, 1991
$$INDEX BEGIN **********************************************************
NOTICES
$$INDEX N1 *************************************************************
WORLD AIDS FOUNDATION
Fogarty International Center
Index: FOGARTY INTERNATIONAL CENTER
$$INDEX N2 *************************************************************
NEW WORLD MONKEYS AVAILABLE FOR BIOMEDICAL RESEARCH
Public Health Service
Index: PUBLIC HEALTH SERVICE
$$INDEX N3 *************************************************************
NATIONAL WORKSHOPS ON "PROTECTION OF HUMAN SUBJECTS"
National Institutes of Health
Food and Drug Administration
Index: NATIONAL INSTITUTES OF HEALTH
FOOD AND DRUG ADMINISTRATION
$$INDEX N4 *************************************************************
ANNUAL REPORT AND ASSURANCE ON POSSIBLE SCIENTIFIC MISCONDUCT
Public Health Service
Index: PUBLIC HEALTH SERVICE
NOTICES OF AVAILABILITY (RFPs AND RFAs)
$$INDEX R1 *************************************************************
VACCINE PRODUCTION FACILITY (RFP)
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES
$$INDEX R2 *************************************************************
ROLE OF HERPES SIMPLEX VIRUS IN THE PATHOGENESIS OF ORAL MUCOSITIS
ASSOCIATED WITH CANCER CHEMOTHERAPY (RFP)
National Institute of Dental Research
Index: DENTAL RESEARCH
$$INDEX R3 05/22/91 ****************************************************
DRUG ABUSE TREATMENT EVALUATION RESEARCH CENTER GRANTS (RFA DA-91-05)
National Institute on Drug Abuse
Index: DRUG ABUSE
$$INDEX R4 05/21/91 ****************************************************
DRUG DISCOVERY GROUPS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
ASSOCIATED WITH ALZHEIMER'S DISEASE (RFA AG-91-09)
National Institute on Aging
Index: AGING
$$INDEX R5 06/10/91 ****************************************************
MEDICAL INFORMATICS RESEARCH TRAINING (RFA LM-91-01)
National Library of Medicine
Index: NATIONAL LIBRARY OF MEDICINE
$$INDEX R6 05/20/91 ****************************************************
EXPLORATORY CENTERS FOR HEALTH BEHAVIOR RESEARCH WITH CHILDREN AND
ADOLESCENTS (RFA NR-91-02)
National Center for Nursing Research
National Institute of Child Health and Human Development
National Institute of Mental Health
Index: NURSING RESEARCH, CHILD HEALTH, HUMAN DEVELOPMENT, MENTAL HEALTH
ONGOING PROGRAM ANNOUNCEMENTS
$$INDEX P1 06/01/91 ****************************************************
THE NCI OUTSTANDING INVESTIGATOR GRANT (PA-91-28)
National Cancer Institute
Index: CANCER
$$INDEX P2 06/01/91 ****************************************************
ACADEMIC AWARD IN ENVIRONMENTAL/OCCUPATIONAL MEDICINE (PA-91-29)
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES
$$INDEX P3 05/10/91 ****************************************************
SHORT-TERM TRAINING FOR MEDICAL STUDENTS IN ENVIRONMENTAL/OCCUPATIONAL
HEALTH (PA-91-30)
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES
ERRATA
$$INDEX E1 04/08/91 ****************************************************
CLINICAL TREATMENT AND CORRELATES OF UPPER GI CARCINOMA (RFA CA-91-03)
National Cancer Institute
Index: CANCER
$$INDEX E2 05/10/91 ****************************************************
PREDOCTORAL FELLOWSHIP AWARDS FOR MINORITY STUDENTS (RFA GM-91-01)
National Institute of General Medical Sciences
Index: GENERAL MEDICAL SCIENCES
$$INDEX E3 *************************************************************
RESEARCH AND DEMONSTRATION GRANTS RELATING TO OCCUPATIONAL SAFETY
AND HEALTH (PA-91-27)
National Institute for Occupational Safety and Health
Index: OCCUPATIONAL SAFETY, OCCUPATIONAL HEALTH
$$INDEX END ************************************************************
NOTICES
$$N1 BEGIN *************************************************************
WORLD AIDS FOUNDATION
P.T. 44; K.W. 0715008, 0502000
Fogarty International Center
The World AIDS Foundation (WAF), jointly sponsored by the U.S.
Department of Health and Human Services and the Institut Pasteur of
Paris, France, announces its intent to support research and education
relating to AIDS in the developing world. The goal of the WAF is to
facilitate information exchange and to assist developing countries to
respond to the AIDS pandemic.
The WAF is particularly interested in projects that are catalytic, and,
once in place, could have a multiplicative effect. The WAF is
specifically interested in supporting:
A) short-term, in-country training for clinicians, allied health
professionals, and technicians;
B) fellowships to support training for national experts;
C) development and testing of new concepts and demonstrations for
preventing the spread of HIV; and
D) highly focused workshops that enhance the scientific process and
transfer knowledge needed in the effort against HIV infections and
AIDS.
The limit of any single funding request to the WAF is $200,000.
Application Procedures:
Concept letters and applications may be prepared in either English or
French. Applicants should submit concept letters for initial
consideration. Following review of concept letters, applicants may be
invited to submit complete proposals. The annual deadline for receipt
of concept letters is April 1.
Concept letters, full applications, and inquiries concerning the
programs of the WAF should be directed to either:
World AIDS Foundation
Assistant Secretary for Health
c/o Director, Fogarty International Center
National Institutes of Health
Building 31, Room B2C39
Bethesda, MD 20892
U.S.A.
or
World AIDS Foundation
c/o Director
Institut Pasteur
28 rue du Docteur Roux
75724 Paris, Cedex 15
FRANCE
$$N1 END ***************************************************************
$$N2 BEGIN *************************************************************
NEW WORLD MONKEYS AVAILABLE FOR BIOMEDICAL RESEARCH
P.T. 34; K.W. 0780000
Public Health Service
The Interagency Research Animal Committee, chartered by
the U.S. Public Health Service (PHS), supports and coordinates a
program with the Pan American Health Organization that makes
possible the importation of New World monkeys into the United
States for use in biomedical research projects. Transfers are
limited to a few species, neither threatened nor endangered. For
information on qualifications for participation, species,
purchase procedures, and other matters, contact:
Interagency Research Animal Committee
Ms. Suzanne Moore
National Institutes of Health
Building 14A, Room 100
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-5424
$$N2 END ***************************************************************
$$N3 BEGIN *************************************************************
NATIONAL WORKSHOPS ON "PROTECTION OF HUMAN SUBJECTS"
P.T. 42; K.W. 0783005
National Institutes of Health
Food and Drug Administration
The National Institutes of Health (NIH) and the Food and Drug
Administration (FDA) are continuing to sponsor a series of workshops on
the responsibilities of researchers, Institutional Review Boards (IRBs),
and institutional officials for the protection of human subjects in
research. The workshops are open to everyone with an interest in
research involving human subjects. The meetings should be of special
interest to those persons currently serving or about to begin serving as
a member of an IRB. Issues discussed at these workshops are relevant to
all other Public Health Service agencies. The current schedule includes
the following:
I. MIDEAST WORKSHOP
DATES: March 4-5, 1991
WORKSHOP SITE:
Friday Center
Laurel Hill Parkway
Chapel Hill, NC 27599-1020
SPONSORS:
University of North Carolina at Chapel Hill
300 Bynum Hall
Chapel Hill, NC 27599-4100
Shaw University
118 E. South Street
Raleigh, NC 27611
REGISTRATION CONTACT:
Mr. Al Dawson
Director
Friday Center
Laurel Hill Parkway
C. B. 1020
Chapel Hill, NC 27599-1020
Telephone: (919) 962-1106
TOPIC: "Interpreting the Federal Code for the Protection of Human
Subjects"
II. MIDWEST WORKSHOP
DATES: April 11-12, 1991
WORKSHOP SITE:
Ramada Inn, Lakeshore
4900 South Lake Shore Drive
Chicago, IL 60615
SPONSORS:
University of Chicago
970 East 58th Street
Chicago, IL 60637
Chicago State University
95th Street at King Drive
Chicago, IL 60628
REGISTRATION CONTACT:
Mr. Arnold L. Aronoff
Associate Director
Faculty and Administrative Services
University Research Administration
University of Chicago
970 East 58th Street
Chicago, IL 60637
Telephone: (312) 702-8669
TOPIC: "Cultural Diversity, Ethics, and Research: A Workshop on Human
Subject Protection"
NIH/FDA have planned national human subject protections workshops in
other parts of the United States. For further information regarding
these workshops contact:
Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Building 31, Room 5B59
Bethesda, MD 20892
Telephone: (301) 496-8101
$$N3 END ***************************************************************
$$N4 BEGIN *************************************************************
ANNUAL REPORT AND ASSURANCE ON POSSIBLE SCIENTIFIC MISCONDUCT
P.T. 34; K.W. 1014006, 1014004
Public Health Service
Effective Date: March 5, 1991
The Public Health Service (PHS) scientific misconduct regulations,
42 CFR 50 Subpart A, "Responsibilities of PHS Awardee and
Applicant Institutions for Dealing With and Reporting Possible
Misconduct in Science", require institutions report annually
to the Office of Scientific Integrity (OSI), about their
handling of allegations, inquiries and investigations into
possible scientific misconduct, in connection with research for
which PHS funds have been requested or received. An
annual update of their institutional assurance also must be reported to
the OSI.
The annual report forms were mailed by the OSI in December 1990
to the signatory official of 2,600 institutions that had filed
an Initial Assurance with OSI for 1990. Most institutions did
return the completed form by the January 1991 deadline; others
received calls or letters about their reports. However, annual
reports for approximately 500 of the smaller institutions have
still not been received by the OSI. They are needed now.
An updated, active assurance is a requirement for an institution
to remain eligible to apply for or receive grants, fellowships,
and cooperative agreements for research funds from the PHS in
1991. The OSI Staff will be updating the approved assurance
file in mid-March to change the assurance status to "inactive"
for those institutions that have not yet submitted annual
reports.
For further information, please call immediately:
Dr. Alan Price, Ms. Carolyn Bowman, or Mr. John Allison
Office of Scientific Integrity
NIH Building 31, Room B1C39
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-2624 (this is not a toll-free number)
FAX: (301) 402-0238
$$N4 END ***************************************************************
NOTICES OF AVAILABILITY (RFPs AND RFAs)
$$R1 BEGIN NIAID-91-36 *************************************************
VACCINE PRODUCTION FACILITY
RFP AVAILABLE: NIAID-91-36
P.T. 34; K.W. 0740075, 1002045
National Institute of Allergy and Infectious Diseases
The Division of Microbiology and Infectious Diseases,
National Institute of Allergy and Infectious Diseases,
requires one Vaccine Production Facility. This
contractor must have the professional capabilities and
facilities to operate a vaccine production laboratory
to prepare live viral, inactivated viral, and subunit
candidate vaccines for evaluation in humans. The vaccines
must be prepared in accordance with the regulations and
guidelines established by the Food and Drug Administration
for materials to be tested in humans. Candidate vaccines
to be produced include, but are not limited to, influenza
viruses, respiratory syncytial virus, parainfluenza viruses,
rotaviruses, and subunit preparations from these agents. The
offeror's facility must meet requirements listed in the Code of
Federal Regulations for an establishment engaged in the
preparation of live and inactivated virus vaccines
licensed for human use by the Office of Biologics
and provide adequate documentation of such qualifications. If
not in full compliance, the offeror must describe what efforts
have been made to bring the facility into compliance. The
offeror is subject to inspection under the "Good Laboratory
Practices Act" and the "Good Manufacturing Act." It is
expected that the contract will have a five (5) year period
of performance. Any responsible offeror may submit a proposal,
which will be considered by the Government.
The issuance date of the RFP will be on March 11, 1991 and
proposals will be due by the close of business on April
26, 1991.
Requests for the RFP must be directed to:
Merilee Rahe-Stoline
Contract Management Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Control Data Building, Room 326P
Bethesda, MD 20892
Please
provide this office with two self-addressed mailing
labels. This advertisement does not commit the Government
to award a contract.
$$R1 END ***************************************************************
$$R2 BEGIN NIH-NIDR-2-91-5R ********************************************
ROLE OF HERPES SIMPLEX VIRUS IN THE PATHOGENESIS OF
ORAL MUCOSITIS ASSOCIATED WITH CANCER CHEMOTHERAPY
RFP AVAILABLE: NIH-NIDR-2-91-5R
P.T. 34; K.W. 0745005, 0740012, 0755015
National Institute of Dental Research
The National Institute of Dental Research (NIDR) has a requirement
to study the role of herpes simplex virus (HSV) in the
pathogenesis of oral mucositis associated with intensive
chemotherapy, and to determine whether the antiviral agent
acyclovir can reduce the incidence and severity of mucositis
in severely immunocompromised patients. The study will
consist of a double-blind, placebo-controlled trial of daily
oral acyclovir for the prevention of HSV infection and
mucositis in HSV-seropositive patients undergoing intensive
chemotherapy for the treatment of leukemias or lymphomas. At
the completion of this two-year study, an analysis will be
made of the severity and frequency of oral ulcerations and the
association of HSV culture/antigen-positive lesions in patients
on acyclovir and those on placebo. If the study demonstrates
that herpes simplex virus is involved in the pathogenesis of
oral mucositis and that acyclovir can reduce the frequency and/or
severity of mucositis, then an informed recommendation can be
made that all HSV seropositive patients undergoing intensive
chemotherapy for acute leukemia or lymphoma receive routine
prophylactic acyclovir therapy for each course of chemotherapy.
The NIDR expects to make one award from this solicitation.
RFP NIH-NIDR-2-91-5R will be available on or about March 18,
1991, with proposals due on or about April 30, 1991.
The RFP package will be available upon written request to:
Marilyn R. Zuckerman, Contracting Officer
Contract Management Section, NIDR
National Institutes of Health
Westwood Building, Room 521
5333 Westbard Avenue
Bethesda, MD 20892
$$R2 END ***************************************************************
$$R3 BEGIN DA-91-05 ****************************************************
DRUG ABUSE TREATMENT EVALUATION RESEARCH CENTER GRANTS
RFA AVAILABLE: DA-91-05
P.T. 04; K.W. 0404009, 0795005
National Institute on Drug Abuse
Application Receipt Date: May 22, 1991
PURPOSE
The purpose of this initiative is to
establish and support Centers to conduct
interdisciplinary research on the effectiveness of drug
abuse treatment.
RESEARCH OBJECTIVES
The Abuse Treatment Evaluation
Research Center Grant Program is designed to complement
the investigator initiated research grants program of the National
Institute on Drug Abuse (NIDA) by providing long-term
support for interdisciplinary evaluative research on
drug abuse treatment. The program is intended to
attract investigators in the behavioral, social, and
biomedical sciences to conduct evaluative research on
the treatment of drug abuse, and to provide a stable
environment for such persons to engage in treatment
research. A Center is expected to become a significant
regional or national research resource. Centers funded
under this announcement will conduct treatment
evaluation research and participate actively
in and cooperate with NIDA's programmatic efforts to
systematically review, coordinate, and integrate
research on treatment populations process, and
outcomes.
A variety of designs and research strategies may be
employed to evaluate existing treatment programming and
related interventions. Both field studies and
controlled (randomized) studies may be used, as well as
secondary analyses to investigate issues of interest to
treatment evaluations. Areas for investigation
potentially include comparative effectiveness of
treatment program types for well-defined client groups,
treatment process, the structure of treatment, studies
of specific modalities, outreach, differential
attractiveness of treatment, client-treatment matching,
the role of non-treatment factors, correctional
treatment, treatment of drug abuse in primary health
care delivery systems, effectiveness of alternative
treatments, (i.e., not designed primarily for drug abusers)
treatment improvement, treatment for
specific drugs of abuse, aftercare and relapse
prevention, treatment careers, and cohort-based studies
of long-term outcomes. Methodologically oriented
studies may also be appropriate activities for the
Center under this program.
SPECIAL
IMPLEMENTATION OF ADAMHA POLICIES CONCERNING INCLUSION
OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY
POPULATIONS
Applications/proposals for ADAMHA grants and
cooperative agreements are required to include both
women and minorities in study populations for clinical
research, unless compelling scientific or other
justification for not including either women or
minorities is provided. This requirement is intended
to ensure that research findings will be of benefit to
all persons at risk of the disease, disorder, or
condition under study. For the purpose of these
policies, clinical research involves human studies of
etiology, treatment, diagnosis, prevention, or
epidemiology of diseases, disorders or conditions,
including but not limited to clinical trials; and
minorities include U.S. racial/ethnic minority
populations (specifically: American Indians or Alaskan
Natives, Asian/Pacific Islanders, Blacks, and
Hispanics).
ADAMHA recognizes that it may not be feasible or
appropriate in all clinical research projects to
include representation of the full array of U.S.
racial/ethnic minority populations. However,
applicants are urged to assess carefully the
feasibility of including the broadest possible
representation of minority groups.
Applications should include a description of the
composition of the proposed study population by gender
and racial/ethnic group, and the rationale for the
numbers and kinds of people selected to participate.
This information should be included in the form PHS 398
in Section 2, A-D of the Research Plan AND summarized
in Section 2, E, Human Subjects.
Applications should incorporate in their study design
gender and/or minority representation appropriate to
the scientific objectives of the work proposed. If
representation of women or minorities in sufficient
numbers to permit assessment of differential effects is
not feasible or is not appropriate, the reasons for
this must be explained and justified.
The rationale may relate to the purpose of the research, the
health of the
subjects, or
other compelling circumstances (e.g., if in the only
study population available, there is a disproportionate
representation in terms of age distribution, risk
factors, or incidence/prevalence of one gender or
minority/majority group).
If the required information is not contained within the
application, the application will be returned. Peer
reviewers will address specifically whether the
research plan in the application conforms to these
policies. If gender and/or minority
representation/justification are judged to be
inadequate, reviewers will consider this as a
deficiency in assigning the priority score to the
application.
APPLICATION PROCEDURES
Applicants must use the standard PHS 398 (rev. 10/88)
grant application form. When applying, type in item 2
of face page of PHS 398, the name of this announcement,
"Drug Abuse Treatment Research Center Program, RFA DA-
91-05." Application kits are available from university
grant offices and from the Division of Research Grants,
National Institutes of Health, Westwood Building, Room
240, 5333 Westbard Avenue, Bethesda, Maryland 20892;
Telephone (301) 496-7441.
Applicants must affix the RFA label available in the
PHS 398 to the bottom of the face page. Failure to use
this label could result in delayed processing of the
application such that it may not reach the review
committee in time for review.
The original and six (6) copies of the application must be
submitted to:
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892
ELIGIBILITY
Applications for research grants may be
made by any public or private non-profit or for-profit
institutions such as universities, colleges, and
hospitals. Women and minority investigators are
encouraged to apply.
REVIEW PROCESS AND CRITERIA
The Division of Research
Grants, NIH, serves as a central point for receipt of
applications for most discretionary HHS grant programs.
Applications received under this announcement will be
assigned to an initial review group (IRG) convened by NIDA.
The IRG will review the applications for
scientific and technical merit. Notification of the
review recommendations will be sent to the applicant
after the initial review. Applications will receive a
second-level review by the National Advisory Council on
Drug Abuse, whose review may be based on policy
considerations as well as scientific merit. Only
applications recommended for approval by the Council
may be considered for funding.
AWARD CRITERIAA
Applications recommended for approval
by the National Advisory Council on Drug Abuse will be
considered for funding on the basis of overall
scientific and technical merit of the Center proposal
as determined by peer review, appropriateness of budget
estimates, NIDA program needs and balance, NIDA policy
considerations, adequacy of provisions for the
protection of human subjects, and availability of
funds.
AVAILABILITY OF FUNDS
In fiscal year 1991, an estimated $2 million will be available to
support new grants under this announcement. The actual amount of
funding available will depend on appropriated funds and program
priorities at the time of award.
INQUIRIES
Prospective applicants may obtain
additional information regarding the development of
Drug Abuse Treatment Evaluation Research Center grant
applications and advice regarding the
feasibility/appropriateness of such applications by
contacting:
Frank M. Tims, Ph.D.
Deputy Chief, Treatment Research Branch
Division of Clinical Research
National Institute on Drug Abuse
Parklawn Building, Room 10A-30
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-4060
For fiscal and administrative matters, contact:
Grants Management Branch
National Institute for Drug Abuse
Parklawn Building, Room 8A54
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-6710
This program is described in the Catalog of Federal
Domestic Assistance No. 13.279. Grants will be awarded
under the authority of Sections 301 and 515 of the
Public Health Service Act, as amended (42 USC 241 and
42 USC 290), and administered in accordance with the
PHS Grants Policy Statement and Federal Regulations at
42 CFR Part 52, and 45 CFR Part 74. This program is
not subject to the Intergovernmental review
requirements of Executive Order 12372 or Health Systems
Agency review.
$$R3 END ***************************************************************
$$R4 BEGIN AG-91-09 FULL-TEXT ******************************************
DRUG DISCOVERY GROUPS FOR THE TREATMENT OF COGNITIVE
IMPAIRMENT ASSOCIATED WITH ALZHEIMER'S DISEASE
RFA AVAILABLE: AG-91-09
P.T. 34; K.W. 0715180, 0740020, 0755025
National Institute on Aging
Letter of Intent Receipt Date: April 1, 1991
Application Receipt Date: May 21, 1991
BACKGROUND
The National Institute on Aging (NIA) invites Program Project
applications (P01) for the establishment of Drug Discovery
Groups for the Treatment of Cognitive Impairment Associated
With Alzheimer's Disease. The U.S. Congress, as part of the
Fiscal Year 1991 appropriation, has mandated that NIA
"explore new treatment and management methods, including
testing promising drugs, such as nerve growth factor and
acetylcarnitine, that could safely and effectively slow or
reverse the symptoms of Alzheimer's disease."
RESEARCH OBJECTIVES AND SCOPE
The objective of this solicitation is to stimulate multi-
center multi-disciplinary preclinical research in the design,
development and testing of novel compounds aimed at slowing,
halting, or, if possible, reversing the progressive decline
in cognitive function in Alzheimer's disease victims. This
initiative is intended to stimulate basic research and
development efforts which go beyond those already underway or
likely to be undertaken by pharmaceutical firms in the
foreseeable future. Compounds are needed to correct or
improve the functioning at various sites along the signal
transduction pathway; e.g. receptors, channels, membrane,
second and third messenger, phosphorylation, and signal
amplification stages. The discovery of compounds and
treatments should be aimed to ameliorate fundamental
processes of the neural dysfunction and cell death associated
with the disease. The aim is to encourage innovative
approaches to the treatment of AD.
MECHANISM OF SUPPORT
Awards will be made as Program Projects (P01). Funding of at
least 3 awards is anticipated. Each award is limited to
$750,000 total cost per year. The amount spent will be
dependent on the continuing availability of funds for this
purpose and the quality and diversity of approved
applications. The start date will be on or before September
30, 1991.
APPLICATION AND REVIEW PROCEDURES
In preparing applications, instructions for PHS Form 398
(10/88 revision, reprinted 9/89), supplemental information
available from NIA program staff, and additional instructions
included in the full RFA should be used. Proposals judged by
staff to be nonresponsive to the RFA will be administratively
withdrawn and returned to the applicant without review.
Responsive proposals may then receive a preliminary review by
a subcommittee of the review panel to establish those
applications deemed to be competitive. Those judged
noncompetitive will be so designated, and an abbreviated
summary statement noting the major deficiencies will be sent
to the principal investigator. Applications judged to be
competitive will be given full review by a special review
group convened by NIA. Following review by the initial
review group, the applications will be considered by the
National Advisory Council on Aging.
Applicants should obtain the full RFA and supplemental
information and discuss their plans with and direct any other
inquiries to:
Neil Buckholtz, Ph.D.
NNA, NIA, NIH
Building 31, Room 5C35
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-9350
FAX: (301) 496-1494
Inquiries regarding fiscal matters may be addressed to:
Mr. Joseph Ellis
Grants Management Offiver
National Institute on Aging
Building 31, Room 5C07
Bethesda, MD 20892
Although not a prerequisite for applying, potential
applicants are encouraged to submit to Dr. Buckholtz, at the
address indicated above, a non-binding letter of intent to
apply by April 1, 1991. Applications must be complete and
received by May 21, 1991.
$$R4 END ***************************************************************
$$R5 BEGIN LM-91-01 FULL-TEXT ******************************************
MEDICAL INFORMATICS RESEARCH TRAINING
RFA AVAILABLE: LM-91-01
P.T. 22; K.W. 1004017, 1004000, 0720005, 0710030
National Library of Medicine
Letter of Intent Receipt Date: May 1, 1991
Application Receipt Date: June 10, 1991
PURPOSE
The National Library of Medicine (NLM) invites training grant
applications in a single competition for predoctoral and
postdoctoral research training in medical informatics.
Applications may be for the creation of new training centers
or for the renewal of existing NLM-supported training
programs. This training will help meet a growing need for
qualified, talented investigators, well prepared to address
information problems in health care, health professional
education, and biomedical research.
Applications must clearly indicate that the
primary intent of the program is preparation for an academic
career in Medical Informatics. Applications must describe
the process by which trainees will become familiar with the
many relevant disciplines. To prepare trainees for research
careers in a demanding research environment, the sponsorship
of a research-oriented, academic health sciences institution
is critical. It is expected that the core of training will
emphasize the synthesis, organization, retrieval, and
effective management of knowledge. The curricula should be
inter-disciplinary by including topics in medicine and the biological
sciences, the cognitive sciences, information science, and
computer science. Training sites must offer an excellent
setting for instruction, involvement in important health
computer science research, and opportunities for meaningful
trainee involvement in such research.
OBJECTIVES AND SCOPE
In addition to the general goal of assisting in the
education of persons to be able to take academic positions to
conduct research and teach medical informatics, several more
specialized additions to the training programs are likely to
become available during the next few years to enhance
research training grants approved in the FY 1991 competition.
Consequently, NLM invites applicant institutions to include
their plans for such possible enhancements within the
application. Some potential enhancement areas (described in
the full RFA) are high performance computing and
communication, biotechnology, cancer, and information
systems. Dental informatics is another area for which
additional training slots may become available in the
future.
MECHANISM OF SUPPORT
This RFA will use the T15 grant mechanism. NLM plans to
make available approximately $3 million for this program in
FY 1992. It is expected that six to ten training grants
will be awarded; however, actual award of grants pursuant to
this RFA is necessarily contingent upon receipt of funds
appropriated for this purpose. These awards are authorized
by the Medical Library Assistance Act and are not part of
the National Research Service Awards Program of the Public
Health Service. Prior to initial scientific merit review, a
triage mechanism may be employed to screen out applications
that are clearly noncompetitive or nonresponsive to the RFA.
Such applications would be returned to the applicant.
APPLICATION SUBMISSION
Letter of Intent: Prospective applicants are asked to submit by May 1,
1991, a letter of intent that includes a descriptive title, the name and
address of the Principal Investigator, the names and addresses of any
other key investigators, and any other participating institutions.
Application form PHS-398 (rev. 10/88) must be
used in applying. To identify responses to this
announcement, check "yes" and type the RFA number and title
[RFA LM-91-01, MEDICAL INFORMATICS RESEARCH TRAINING] in
item 2 on page 1 of the grant application. The RFA label
provided with the instructions must be affixed to the bottom
of the face page. Failure to use this label could result in
delayed processing of your application such that it may not
reach the review committee in time for review.
The completed original application and six (6) copies must
be mailed to:
Division of Research Grants
National Institute of Health
Westwood Building, Room 240
Bethesda, MD 20892**
Applications must be received by June 10, 1991. Applications received
after that date will be returned to the applicant. The review process
will be completed in October 1991. Funding around July 1, 1992 is
anticipated.
INQUIRIES
A more detailed RFA may be obtained from:
Roger W. Dahlen, Ph.D.
Chief, Biomedical Information
Support Branch
Extramural Programs
National Library of Medicine
8600 Rockville Pike
Building 38A, Room 5S522
Bethesda, MD 20894
Telephone: (301) 496-4221
FAX: (301) 402-0421
For fiscal and administrative matters, contact:
Ruth Bortz
National Library of Medicine
8600 Rockville Pike
Building 38A, Room 5S522
Bethesda, MD 20892
Telephone: (301) 496-4253
$$R5 END ***************************************************************
$$R6 BEGIN NR-91-02 FULL-TEXT ******************************************
EXPLORATORY CENTERS FOR HEALTH BEHAVIOR RESEARCH WITH
CHILDREN AND ADOLESCENTS
RFA AVAILABLE: NR-91-02
P.T. 34, AA; K.W. 0404000, 0715020, 0745035
National Center for Nursing Research
National Institute of Child Health and Human Development
National Institute of Mental Health
Letter of Intent Receipt Date: April 15, 1991
Application Receipt Date: May 20, 1991
PURPOSE
The National Center for Nursing Research (NCNR), the National Institute
of Child Health and Human Development (NICHD) and the National Institute
of Mental Health (NIMH) invite applications from interested institutions
to establish multidisciplinary exploratory centers to investigate health
behavior development in children and adolescents (ages 8-18). It is
anticipated that approximately 6 exploratory centers will be funded.
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of Healthy People 2000, a
PHS-led national activity for setting priority areas. This RFA,
"Exploratory Centers for Health Behavior Research with Children and
Adolescents," is related to the priority area of the development of
several health promotion behaviors. Potential applicants may obtain a
copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0) or
Healthy People 2000 (Summary Report: Stock No. 017-001-00473-1) through
the Superintendent of Documents, Government Printing Office, Washington,
D.C. 20402-9325 (Telephone 202-783-3238).
BACKGROUND
Recent reports highlight the significance of behaviors relating to diet,
physical activity, alcohol and tobacco use, injuries, and sexual
behaviors that begin in childhood and adolescence, compromise health in
the short term and have major long-range implications for the onset of
chronic disease including cardiovascular disease and cancer. This RFA
seeks empirically-based multidisciplinary research that will form the
foundation for biomedical, behavioral and nursing interventions in
health promotion and disease prevention, and facilitate health-enhancing
patterns of behavior in children and adolescents.
SPECIFIC OBJECTIVES AND AREAS OF INTEREST
Applicants are invited to apply for support of projects to address
issues including but not limited to:
A Behavioral Epidemiology-Identification and Distribution of
Behavioral Risk Factors.
B Establishment, Change and Maintenance of Health Related Behaviors.
C Basic Behavioral Biological Mechanisms.
ELIGIBILITY
Institutions or consortia of institutions are eligible to apply if they
have at least two Principal Investigators with any PHS agency or
comparable peer reviewed research project (R01) grants that are
currently active in health and behavior research.
MECHANISM OF SUPPORT
The support mechanism for this RFA is the Exploratory Center Grant
(P20). The Exploratory Center Grant consists of (1) an administrative
and planning core providing administrative, coordinating, research
planning, logistical, and/or methodological (e.g., research design, data
analysis) support and (2) small-scale studies. The initial award period
is for three years, and the award may not be renewed. Grants will be
administered in accordance with the PHS Grants Policy Statement
(10/01/90).
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations. If women or minorities are not included in the study
populations for clinical studies, a specific justification for this
exclusion must be provided. Applications without such documentation
will not be accepted for review.
METHOD OF APPLYING
Prior to submission of the formal application, consultation with NCNR,
NICHD and/or NIMH concerning the technical and substantive aspects of
preparing the application is recommended. Copies of the complete RFA
can be obtained from the program staff listed below:
Direct inquiries to:
NCNR NICHD
Sharlene M. Weiss, PhD, RN Peter Scheidt, MD, MPH
Chief, Health Promotion/Disease Medical Officer
Prevention Branch, NCNR, NIH Human Learning and Behavior
9000 Rockville Pike Branch, NICHD, NIH,
Building 31, Room 5B09 9000 Rockville Pike
Bethesda, MD 20892 Bethesda, MD 20892
Telephone: (301) 496-0523 Telephone: (301) 496-6591
NIMH
Leonard Mitnick, Ph.D.
Chief, Basic Prevention and Behavioral Medicine Research
Branch, NIH
Room 11C-06
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-4337
$$R6 END ***************************************************************
ONGOING PROGRAM ANNOUNCEMENTS
$$P1 BEGIN *************************************************************
THE NCI OUTSTANDING INVESTIGATOR GRANT
PA: PA-91-28
P.T. 34; K.W. 0715035, 0710030
National Cancer Institute
Application Receipt Date: June 1, 1991
SUMMARY AND PURPOSE
The National Cancer Institute (NCI) will continue to accept new
applications for the Outstanding Investigator Grant (OIG), as well as
competing continuation applications from currently funded OIG recipients
in the fifth year of the initial award period. The purpose of the OIG
is to encourage investigators to continue or embark on projects of
unusual potential in cancer research. Emphasis will be placed on
evidence of recent substantive contributions (i.e., seminal ideas and
innovative approaches to resistent problems) and the potential for
continued work of high caliber.
This announcement significantly modifies available applicable guidelines
for the OIG. Special attention should be given to the requirements for
"Eligibility" and to the "General Requirements" for preparation of new
and competing continuation applications as noted below.
ELIGIBILITY
Applications may be submitted only by domestic institutions on behalf of
investigators who have recently demonstrated outstanding research
productivity for at least five years. There are no age restrictions.
Only United States citizens, nationals or permanent residents may be
presented as candidates for this grant.
Applications will be accepted by the NCI only when they are
cancer-related as defined by the Division of Research Grants (DRG) grant
referral guidelines. Investigators whose current research support is
derived predominantly from sources other than the NCI may not be
eligible as OIG awardees. As a general rule, Investigators will be
allowed to consolidate ONLY NCI supported active cancer-related peer
reviewed grants into the OIG research effort. In this regard applicants
are encouraged to discuss their research objectives with appropriate NCI
officials before applying.
The OIG Principal Investigator is required to commit 75 percent of his
or her time and effort to cancer research supported by the OIG, and the
institution sponsoring the OIG application is required to commit itself
to providing 25 percent of the Investigator's salary support. However,
the NCI will entertain requests, on a case-by-case basis, for time and
effort commitments of less than 75 percent (with a proposed minimum of
50 percent) to the OIG project based upon allowable retention of other
ongoing peer reviewed grants.
Applications that do not meet all of the above eligibility criteria or
that have not had approval from the NCI as exceptions to the above
criteria will be returned to the applicant.
GENERAL REQUIREMENTS
New (Type 1) and competing continuation (Type 2) OIG applicants will be
required to provide a detailed ("evaluable") proposal emphasizing
his/her accomplishments prior to (Type 1) and during (Type 2) the first
grant period and a detailed description of the activities to be
supported under the next competing award period. The budget request
must be in specific terms and a zero-based budget* should be developed
to assist reviewers in making explicit budget recommendations.
REVIEW PROCEDURES
Applications will be assigned to an appropriate subset of a nationwide
panel of recognized cancer investigators convened by the Division of
Extramural activities, NCI and reviewed for scientific and technical
merit. Following review by the initial review group, the applications
will receive a second-level review by the National Cancer Advisory Board
(NCAB) prior to a final funding decision by the NCI.
HOW TO APPLY
o The date of receipt of all OIG applications, including competing
continuation applications has been changed to June 1 of each year. They
will be processed for review at the earliest possible meeting of the
NCAB.
o Applications for this award should be made on Form PHS 398 (rev.
10/88) in accordance with instructions in this Announcement. These
forms are available at most academic or research institutional business
offices and from the Office of Grants Inquiries, Division of Research
Grants, National Institutes of Health, Room 449 Westwood Building, 5333
Westbard Avenue, Bethesda, Maryland 20892.
o The title "NCI OUTSTANDING INVESTIGATOR GRANT, PA-91-28" must be typed
in section 2 on the first page of the application.
o A letter indicating clear and continual institutional commitment by
the Institution to the applicant must accompany the application in order
for the NCI to begin the review process.
o Applications must be accompanied by a curriculum vitae and a complete
bibliography. Abbreviated curricula vitae of all professional persons
(doctoral level or equivalent) listed on the personnel page should be
included. Reprints of no more than five publications may be submitted.
For a new application that proposes primarily the consolidation of
existing NCI-supported research grants, the prose portion may not exceed
ten typewritten pages. For these applications, detailed descriptions of
methods are not required because the evaluation of the new OIG
application will be based mostly on the applicant's track record in the
context of current peer-reviewed support. However, these new
applications must outline the main objectives to be pursued and discuss
the significance of the research. When objectives are proposed that are
outside the context of current peer-reviewed activities, portions of the
application addressing those aims should be written in more detail.
Therefore, for applications proposing new research areas, and for
competing renewal applications, up to 18 pages of prose are allowable.
o The applicant investigator and his/her institution must present a
workable plan for consolidation of the applicant's current research
support and conversion of staff and facilities to be supported by the
OIG. This must be submitted as a separate section of the grant
application immediately following the budget section.
o The original and six legible copies of the application should be
submitted to DRG, NIH, as directed in the instructions of the grant
application.
INQUIRIES
All potential applicants of this award are advised that the full text of
this Program Announcement, containing currently applicable guidelines,
is now available and should be requested prior to submitting an
application for the June 1, 1991 receipt date.
Please direct inquiries for further information on application
development to:
Barbara S. Bynum
Director
Division of Extramural Activities
National Cancer Institute
Building 31, Room 10A03
Bethesda, MD 20892
Telephone: (301) 496-5147
For fiscal and administrative matters, contact:
Crystal Elliott
Grants Management Specialist
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD 20892
Telephone: (301) 496-7800 x19
* Budget request should justify each item for which support is requested
and should not be presumed to include all funds currently available to
the Principal Investigator under active grant awards.
$$P1 END ***************************************************************
$$P2 BEGIN *************************************************************
ACADEMIC AWARD IN ENVIRONMENTAL/OCCUPATIONAL MEDICINE
PA: PA-91-29
P.T. 34; K.W. 0725020, 0725000, 0720005
National Institute of Environmental Health Sciences
Application Receipt Date: June 1, 1991
The National Institute of Environmental Health Sciences
(NIEHS) announces its second national competition for
Environmental/Occupational Medicine Academic Awards which
first appeared in the NIH Guide, Vol. 19, No. 8, February
23, 1990, Page 9. The award will have the dual purpose of
improving the quality of environmental/occupational medicine
curricula and of fostering graduate research careers in
environmental/occupation medicine. Each school of medicine
or osteopathy in the United States and its possessions or
territories is eligible to compete for Environmental/
Occupational Medicine Academic Award for a project period
that does not exceed five years and, if successful, to
receive the Award once only. The number of new awards made
each year will depend on the availability of funds.
For the purposes of the Environmental/Occupational Medicine
Academic Award, the term environmental/occupational medicine
refers to the area of medicine concerned with the
development of knowledge and the application of knowledge
directed at the diagnosis, treatment, and prevention of
adverse human health effects from environmental/occupational
exposures to toxic agents. This includes adverse health
effects in infants, children, and adults who are at risk of
developing such health problems and the reduction of
preventable complications or disability in persons of all
ages who have already developed such diseases.
NIEHS initiated the Environmental/Occupational Medicine
Academic Award Program to provide a stimulus for development
of an environmental/occupational medicine curriculum in
those schools that do not have one and to strengthen and
improve the environmental/occupational medicine curriculum
in schools that do. Awards provide support to applicant
faculty members for their educational development and for
implementation or expansion of the curriculum in
environmental/occupational medicine.
HEALTHY PEOPLE 2000
The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of
Healthy People 2000, a PHS-led national activity for setting
priority areas. This Program Announcement, Academic Award
in Environmental/Occupational Medicine, is related to the
priority area of environmental health.
Potential applicants may obtain a copy of Health People 2000
(Full Report: Stock No. 017-001-00474-0) or Healthy People 2000
(Summary Report: Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office,
Washington, D.C. 20402-9325 (Telephone 202-783-3238).
Applications must be received by June 1, 1991, for review at
the January meeting of the National Environmental Health
Sciences Advisory Council. Awards will be made with a
beginning date of July 1, 1992. Copies of the Program
Guidelines are currently available from:
Annette Kirshner, Ph.D.
Scientific Programs Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institute of Health
P. O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-0488
For fiscal and administrative matters, contact:
David L. Mineo
Grants Management Officer
Grants Management Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institutes of Health
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-1373
The programs of the National Institute of Environmental
Health Sciences are identified in the Catalog of Federal
Domestic Assistance, Number 93.894. Awards will be made
under the authority of the Public Health Service Act,
Section 301 (42 USC 241) and administered under PHS grant
policies and Federal regulations, most specifically 42 CFR
Part 52 and 45 CFR Part 74. This program is not subject to
the intergovernmental review requirements of Executive Order
12372 or to review by a Health Systems Agency.
$$P2 END ***************************************************************
$$P3 BEGIN *************************************************************
SHORT-TERM TRAINING FOR MEDICAL STUDENTS IN ENVIRONMENTAL/
OCCUPATIONAL HEALTH
PA: PA-91-30
P.T. 34; K.W. 0725020, 0725000, 0720005
National Institute of Environmental Health Sciences
Application Receipt Date: May 10, 1991
The purpose of this second announcement, which first appeared
in the NIH Guide, Vol. 19, No. 9, March 2, 1990, Page 10, is
to solicit applications for short-term training of medical
students in disciplines related to environmental and
occupational medicine. Two types of mechanisms are
available.
Medical schools at which there is a currently active
National Institute of Environmental Health Sciences (NIEHS)
Institutional Training Grant (T32) may submit a supplemental
application to support 3-5 medical students for summer or
off-term research. The period of support may not exceed
three months. Requests for short-term training may be
submitted only at the time of competitive renewal.
Medical schools that do not currently have an NIEHS
Institutional Training Grant but do have ongoing basic
and/or clinical research activities in areas related to
environmental/occupational health may apply for a National
Research Service Award for Short-Term Training (T35) to
support 3-5 students per year as described above.
HEALTHY PEOPLE 2000
The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of
Healthy People 2000, a PHS-led national activity for setting
priority areas. This Program Announcement, Short-Term
Training for Medical Students in Environmental/Occupational
Health, is related to the priority area of environmental
health.
Potential applicants may obtain a copy of Health People 2000
(Full Report: Stock No. 017-001-00474-0) or Healthy People 2000
(Summary Report: Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office,
Washington, D.C. 20402-9325 (Telephone 202-783-3238).
For additional information and special instructions,
contact:
Annette Kirshner, Ph.D.
Scientific Programs Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institute of Health
P. O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-0488
For fiscal and administrative matters, contact:
David L. Mineo
Grants Management Officer
Grants Management Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institutes of Health
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-1373
$$P3 END ***************************************************************
ERRATA
$$E1 BEGIN *************************************************************
CLINICAL TREATMENT AND CORRELATES OF UPPER GI CARCINOMA
RFA: CA-91-03
P.T. 34; K.W. 0715035, 0705025, 0745070
National Cancer Institute
Letter of Intent Date: February 25, 1991
Application Receipt Date: April 8, 1991
The Division of Cancer Treatment of the National Cancer Institute would
like to clarify Request for Applications (RFA) CA-91-03 with regard to
appropriate upper gastrointestinal (GI) tumor sites. This RFA titled
"Clinical Treatment and Correlates of Upper GI Carcinoma" was published
December 28, 1990. Carcinoma of the upper GI tract is now defined to
include "pancreatic carcinoma" in addition to esophagus and stomach
carcinomas. The RFA invites research grant applications (R01) from
interested investigators to assess new clinical correlates and develop
new treatment modalities in upper gastrointestinal carcinoma.
Written or telephone inquiries concerning the objectives and scope of
this RFA or inquiries about whether or not specific research would be
responsive are encouraged and should be directed to Ms. Diane Bronzert
at the address below.
Ms. Diane Bronzert
Program Director
Cancer Therapy Evaluation Program
Division of Cancer Treatment
National Cancer Institute
Executive Plaza North, Room 734
Bethesda, MD 20892
Telephone: (301) 496-8866
FAX: (301) 496-9384
For fiscal and administrative matters, contact:
Mary Niemiec
DCT Grants
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 242
Bethesda, MD 20892
Telephone: (301) 496-7800
$$E1 END ***************************************************************
$$E2 BEGIN *************************************************************
PREDOCTORAL FELLOWSHIP AWARDS FOR MINORITY STUDENTS
RFA: GM-91-01
P.T. 22, FF; K.W. 072005, 1014002
National Institute of General Medical Sciences
Application Receipt Date: May 10, 1991
The Eligibility Requirements as printed in the NIH Guide for Grants
and Contracts on February 15, 1991, Vol. 20, No. 7, should be
corrected to read:
ELIGIBILITY REQUIREMENTS
An applicant must currently be enrolled in a Ph.D. or M.D./Ph.D.
graduate program in the biomedical sciences, or have been accepted
by and agreed to enroll in such a graduate program the following
academic year.
Eligibility for these awards is limited to students who are U.S.
citizens, non-citizen nationals, and permanent residents from
ethnic/racial groups that are underrepresented in research in the
biomedical sciences. For the purpose of this announcement,
underrepresented minority students are defined as individuals
belonging to a particular ethnic or racial group which has been
determined by the applicant's graduate institution to be
underrepresented in biomedical or behavioral research. In making
these awards, the NIH will give priority consideration to
applications from Black, Hispanic, Native American, and Pacific
Islander and other ethnic or racial group members who have been
found to be underrepresented in biomedical or behavioral research
nationally.
$$E2 END ***************************************************************
$$E3 BEGIN *************************************************************
RESEARCH AND DEMONSTRATION GRANTS RELATING TO OCCUPATIONAL SAFETY
AND HEALTH
PA: PA-91-27
P.T. 34; K.W. 0725020, 0403004, 0715027
Centers for Disease Control
National Institute for Occupational Safety and Health
This Program Announcement was published in the NIH Guide for Grants
and Contracts on February 22, 1991, Vol. 20, No. 8., and contained
an incorrect PA number. The corrected PA number is PA-91-27.
Applications submitted in response to this Program Announcement must
insert the title of this announcement and PA-91-27 on line 2 of the
application face page.
$$E3 END ***************************************************************